Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Lupus nephritis
•
Systemic lupus erythematosus
•
Nephrology
Where do you introduce SGLT2 and GLP1 medications in the sequence of treatments for patients with lupus nephritis?
Related Questions
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
What steroid regimen do you typically use for induction therapy in patients with lupus nephritis?
Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?
Do you require lupus patients with ESKD or advanced CKD to be on minimal immunosuppression around the time of kidney transplantation?
How would you approach the management of a new SLE patient presenting with lupus podocytopathy with FSGS and severe proteinuria (Pr/Cr 18) without immune complex deposition?
Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
How do you treat a patient with new class V lupus nephritis and recent hx of breast cancer on tamoxifen?
